Quarterhill (QTRHF) 40-F 10 Feb 17 2016 FY Annual report (Canada) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2016shares
Document And Entity Information [Abstract]
Document Type	40-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	WILN
Entity Registrant Name	Wi-LAN Inc.
Entity Central Index Key	1,518,419
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding	118,572,181

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Earnings - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 92,876	$ 102,855
Operating expenses
Cost of revenue	64,111	70,400
Research and development		2,430
Marketing, general and administration	9,794	7,462
Foreign exchange (gain) loss	(103)	2,985
Impairment of assets		1,747
Restructuring charges		1,302
Total operating expenses	73,802	86,326
Earnings from operations	19,074	16,529
Interest income	548	428
Earnings before income taxes	19,622	16,957
Provision for income tax expense
Current	5,539	4,013
Deferred	3,031	2,908
Provision for income tax recovery	8,570	6,921
Net and comprehensive earnings	$ 11,052	$ 10,036
Earnings per share
Basic	$ 0.09	$ 0.08
Diluted	$ 0.09	$ 0.08
Weighted average number of common shares
Basic	119,245,581	120,713,535
Diluted	119,245,581	120,720,171

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 106,553	$ 93,431
Short-term investments	1,154	1,120
Accounts receivable (Note 11)	20,357	8,436
Prepaid expenses and deposits	1,293	1,607
Total Current Assets	129,357	104,594
Loan receivable (Note 4)	1,766	1,497
Property and equipment, net (Note 5)	1,240	1,614
Patents, net (Note 6)	123,351	155,213
Deferred tax asset (Note 3)	14,646	17,677
Goodwill	12,623	12,623
Total Assets	282,983	293,218
Current liabilities
Accounts payable and accrued liabilities (Note 9)	15,645	23,205
Current portion of patent finance obligations (Note 8)	10,372	8,085
Total Current Liabilities	26,017	31,290
Patent finance obligations (Note 8)	12,775	19,895
Success fee obligation (Note 9)	47	655
Total Liabilities	38,839	51,840
Commitments and contingencies (Note 12)
Shareholders' equity
Capital stock (Note 10 (c))	419,485	427,781
Additional paid-in capital (Note 10 (d))	21,036	16,549
Accumulated other comprehensive income	16,225	16,225
Deficit	(212,602)	(219,177)
Total Stockholders' Equity	244,144	241,378
Total Liabilities and Stockholders' Equity	$ 282,983	$ 293,218

Consolidated Statements of Cash

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash generated from (used in) Operations
Net earnings	$ 11,052	$ 10,036
Non-cash items
Stock-based compensation	217	847
Depreciation and amortization	34,651	38,164
Foreign exchange (gain) loss	(247)	1,339
Loss on disposal of assets	13	15
Impairment of assets		1,747
Deferred income tax expense	3,031	2,908
Accrued interest income	(269)	(229)
Changes in non-cash working capital balances
Accounts receivable	(11,921)	(6,238)
Prepaid expenses and deposits	314	(1,113)
Payments associated with success fee obligation	(3,007)	(3,736)
Accounts payable and accrued liabilities	3,008	(208)
Cash generated from operations	36,842	43,532
Financing
Dividends paid	(4,527)	(20,082)
Common shares repurchased under normal course issuer bid	(4,225)	(329)
Common shares issued for cash on the exercise of options	11	1,269
Common shares issued for cash from Employee Share Purchase Plan	72	131
Cash used in financing	(8,669)	(19,011)
Investing
Purchase of property and equipment	(48)	(178)
Repayment of patent finance obligations	(5,555)	(18,127)
Purchase of patents	(9,660)	(37,973)
Cash used in investing	(15,263)	(56,278)
Foreign exchange loss (gain) on cash held in foreign currency	212	(1,123)
Net increase (decrease) in cash and cash equivalents	13,122	(32,880)
Cash and cash equivalents, beginning of year	93,431	126,311
Cash and cash equivalents, end of year	$ 106,553	$ 93,431

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Capital Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Deficit [Member]
Beginning Balance at Dec. 31, 2014	$ 245,757	$ 426,037	$ 16,375	$ 16,225	$ (212,880)
Comprehensive earnings (loss):
Net earnings	10,036				10,036
Shares and options issued:
Stock-based compensation expense (Note 10 (d))	847		847
Exercise of stock options (Note 10 (c))	1,269	2,056	(787)
Sale of shares under Employee Share Purchase Plan (Note 10 (c))	131	131
Shares repurchased under normal course issuer bid (Note 10 (c))	(329)	(443)	114
Dividends declared (Note 10 (c))	(16,333)				(16,333)
Ending Balance at Dec. 31, 2015	241,378	427,781	16,549	16,225	(219,177)
Comprehensive earnings (loss):
Net earnings	11,052				11,052
Shares and options issued:
Stock-based compensation expense (Note 10 (d))	217		217
Conversion of deferred stock units to common shares	116	116
Exercise of stock options (Note 10 (c))	11	17	(6)
Sale of shares under Employee Share Purchase Plan (Note 10 (c))	72	72
Shares repurchased under normal course issuer bid (Note 10 (c))	(4,225)	(8,501)	4,276
Dividends declared (Note 10 (c))	(4,477)				(4,477)
Ending Balance at Dec. 31, 2016	$ 244,144	$ 419,485	$ 21,036	$ 16,225	$ (212,602)

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Nature of Business	1. NATURE OF BUSINESS Wi-LAN Inc. (“WiLAN” or the “Company”) is an intellectual property licensing company which develops, acquires, licenses and otherwise enforces a range of patented technologies which are utilized in products in a wide array of markets including communications and consumer electronics, medical, industrial, semiconductor, automotive and aerospace. The Company generates revenue by licensing its patents to companies that sell products utilizing technologies including: Wi-Fi, WiMAX, LTE, CDMA, DSL, DOCSIS, Bluetooth, V-Chip, 3D television, automotive headlight assemblies, semiconductor manufacturing and packaging, medical stent, video streaming, CMOS image sensors, building automation, computer gaming, smart meter monitoring and LED lighting. The Company also generates revenue by licensing patent portfolios on behalf of its partners and, if necessary, the enforcement of their patented technologies.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements of WiLAN include the accounts of WiLAN and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in the consolidated financial statements. The significant accounting policies are summarized below: Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the years. Actual results could differ from those estimates. The significant accounting policies contained herein include estimates and assumptions with respect to best estimate of selling price, determination of discount rates, recoverability of deferred tax assets, determination of indicators of impairment assessment and related impairment assessments, initial estimate of risk of concessions, timing of payments related to patent finance obligations, and the assumptions used in determining the fair value of stock options granted. Revenue Recognition The Company’s revenue consists principally of royalty revenue from licensing its own patent portfolio. The Company may also generate royalty revenue from licensing patent portfolios on behalf of its partners. The Company considers revenue to be earned when it has persuasive evidence of an arrangement, the obligation has been fulfilled in accordance with the terms of the licensing agreement, including delivery and acceptance, the amounts are fixed or determinable and collection is reasonably assured. The Company defers recognizing revenue until such time as all criteria are met. Determination of whether or not these criteria have been met may require the Company to make judgments, assumptions and estimates based upon current information and historical experience. The Company’s revenues consist of fixed fee and running royalty payments. Revenues from running royalty arrangements can be based on either a percentage of sales or number of units sold for which the Company earns revenues at the time the licensees’ sales occur. The licensees are obligated to provide the Company with quarterly or semi-annual royalty reports and these reports are typically received subsequent to the period in which the licensees underlying sales occurred. The Company’s licensees do not, however, report and pay royalties owed for sales in any given reporting period until after the conclusion of that reporting period. As the Company is unable to estimate the licensees’ sales in any given reporting period to determine the royalties due to it, the Company recognizes running royalty revenues based on royalties reported by the licensees during the quarter and when other revenue recognition criteria are met. The Company monitors the receipt of royalty reports to ensure that there is not a disproportionate number of months of revenue in any given fiscal year. Revenues from fixed fee royalty arrangements may consist of one or more installments of cash. The timing and amount of revenue recognized from each licensee depends upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Where agreements include multiple elements, the Company assesses if the deliverables have standalone value upon delivery, and if so, accounts for each deliverable separately. When multiple-deliverables included in an arrangement are separated into different units of accounting, the arrangement consideration is allocated to the identified separate units based on a relative selling price hierarchy. WiLAN determines the relative selling price for a deliverable based on its best estimate of selling price (“BESP”). WiLAN determines BESP by considering its overall pricing objectives and market conditions. Significant pricing practices taken into consideration include discounting practices, the size and volume of transactions, the customer demographic, the geographic area covered by licenses, price lists, licensing strategy, historical standalone licenses and contracted royalty rates. The determination of BESP is made through consultation with and approval by management, taking into consideration the licensing strategy. As part of the partnering agreements with third parties, the Company is able to recover certain out-of-pocket expenses and legal costs. These amounts are included in revenue in the years which the aforementioned revenue criteria is met and the amounts become reimbursable. Revenue arrangements with extended payment terms, where fees are fixed in one or more installments of cash and which contain terms that could impact the amounts ultimately collected, are generally recognized as collection becomes assured. Stock-based Compensation The Company has a share option plan (“Option Plan”) for certain employees, directors and consultants. The Company accounts for stock options using the fair value method. Compensation expense is measured at the estimated fair value of the options at the date of grant and charged to earnings on a straight-line basis over the vesting periods. The amount expensed is credited to additional paid-in capital in the period. Upon the exercise of stock options, cash received is credited to share capital together with any amount previously credited to additional paid-in capital related to the options exercised. Deferred Stock Units (“DSUs” ) The Company has a DSU plan for certain employees and directors. The DSUs vest immediately and the Company has the right to settle the DSUs in either cash or by the issuance of common shares. The liability for outstanding units and related expense for the DSUs are adjusted to reflect the market value of the common shares at each balance sheet date. Restricted Share Units (“RSUs”) The Company has a RSU plan for certain employees and directors. Under the RSU plan, units are settled in cash based on the market value of WiLAN’s common shares on dates the RSUs vest. The RSUs vest over a three-year period. The accrued liability and related expense for the RSUs are adjusted to reflect the market value of the common shares at each balance sheet date. Income Taxes The Company uses the liability method of accounting for income taxes. Deferred income tax assets and liabilities are determined based on the difference between the accounting and tax bases of the assets and liabilities and measured using the enacted tax rates that are expected to be in effect when the differences are estimated to be reversed. In assessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of deferred income tax assets is dependent upon the generation of sufficient future taxable income during the periods prior to the expiration of the associated tax attributes. Cost of Revenue Cost of revenue includes patent licensing expenses, royalty obligations, staff costs (including stock-based compensation) and other costs incurred in conducting license negotiations as well as litigation, the expenses related to the management of the patent portfolio, contingent partner payments and legal fees and amortization expense related to acquired patents, which are expensed as incurred. Research and Development (“R&D”) R&D includes engineering expenses, staff costs (including stock-based compensation) and certain external consultants related to the development efforts, which were expensed as incurred. Computation of Earnings (Loss) Per Share Basic earnings/loss per share is computed using the weighted average number of common shares outstanding during the year. Diluted earnings/loss per share is computed using the treasury stock method. Foreign Currency Translation The Company’s functional currency is the U.S. dollar; monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars at exchange rates prevailing at the balance sheet date. Revenue and expenses are translated at the average rate for the period. The gains and losses from foreign currency denominated transactions are included in foreign exchange gain/loss in the consolidated statement of operations and comprehensive earnings. The Company enters into foreign exchange forward contracts, from time to time, to manage its exposure to currency rate fluctuations related primarily to future cash inflows and outflows of Canadian dollars. The Company does not hold or issue derivative financial instruments for trading or speculative purposes and it has chosen not to designate them as hedges. Therefore these contracts must be fair valued each quarter. The resulting gain or loss on the valuation of these financial instruments is included in foreign exchange gain/loss in the consolidated statement of operations and comprehensive earnings. Cash and Cash Equivalents Cash and cash equivalents comprise cash in bank accounts, term deposits and Guaranteed Investment Certificates (“GICs”) with original maturities of three months or less at the date of the investment. Short-term Investments Short-term investments are designated as “held to maturity” and accounted for at amortized cost using the effective interest rate method. Short-term investments comprise GICs with original maturities of one-year or less at the date of investment and their carrying value approximates their fair value. Loan Receivable The loan receivable is accounted for at amortized cost using the effective interest rate method. Property and Equipment Furniture and equipment is carried at cost less accumulated depreciation. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets as follows: Leasehold improvements term of the lease Computer equipment and software 3 years Furniture and equipment 5 years Patents Patents include patents and patent rights (hereinafter, collectively “patents”) and are carried at cost less accumulated amortization. Amortization is calculated on the straight-line basis over the estimated useful life or the remaining term of the patent (up to 20 years), whichever is less. Impairment of long-lived assets The Company reviews long-lived assets ("LLA") such as property and equipment and patent asset groups for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. These events and circumstances may include significant decreases in the market price of an asset or asset group, significant changes in the extent or manner in which an asset or asset group is being used by the Company or in its physical condition, a significant change in legal factors or in the business climate, a history or forecast of future operating or cash flow losses, significant disposal activity, a significant decline in the Company's share price, a significant decline in revenues or adverse changes in the economic environment. When significant indicators of impairment exist, LLA impairment is tested using a two-step process. The Company performs a cash flow recoverability test as the first step, which involves comparing the estimated undiscounted future cash flows for the asset group to the carrying amount of the asset group. If the net cash flows of the asset group exceed its carrying amount, the asset group is not considered to be impaired. If the carrying amount of the asset group exceeds the net cash flows, there is an indication of potential impairment and the second step of the LLA impairment test is performed to measure the impairment amount. The second step involves determining the fair value of the asset group. Fair value is determined using valuation techniques that are in accordance with U.S. GAAP, including the market approach, income approach and cost approach. If the carrying amount of the asset group exceeds its fair value, then the excess represents the maximum amount of potential impairment that will be allocated to the asset group, with the limitation that the carrying value of each asset cannot be reduced to a value lower than that of its fair value. The total impairment amount allocated is recognized as a non-cash impairment loss. Goodwill Goodwill is recorded as at the date of the business combination and represents the excess of the purchase price of acquired businesses over the fair value assigned to identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at year end or more frequently if events or changes in circumstances indicate the asset might be impaired. The impairment test is carried out in two steps. In the first step, the carrying value of the reporting unit including goodwill is compared with its fair value. When the fair value of a reporting unit exceeds its carrying value, goodwill of the reporting unit is considered not to be impaired and the second step is unnecessary. The Company has one reporting unit. In the event the fair value of the reporting unit, including goodwill, is less than the carrying value, the implied fair value of the reporting unit’s goodwill is compared with its carrying value to measure the amount of any impairment loss. When the carrying value of goodwill in the reporting unit exceeds the implied fair value of the goodwill, an impairment loss is recognized in an amount equal to the excess. Patent Finance Obligations Patent finance obligations have maturities beyond one year. Patent finance obligations, at inception, are recorded at their fair value using an estimated risk-adjusted discount rate and the carrying value is at amortized cost using the effective interest rate method. Business Segment Information The Company has one operating segment and one reportable segment; Intellectual Property. The Company generates the majority of its revenues in U.S. dollars from several geographic regions; however it has allocated its revenues to the location in which the license originated. Substantially all licenses and revenue are attributable to Canada, as are long-lived assets. Future accounting pronouncements In May 2014, the Financial Accounting Standards Board issued ASU 2014-9, "Revenue from Contracts with Customers". The amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs-Contracts with Customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, "Revenue from Contracts with Customers" which reflects decisions reached by the Financial Accounting Standards Board at its meeting earlier in the year to defer the effective date to fiscal years beginning after December 15, 2017, with early adoption permitted. Under this new standard, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has issued several amendments to the standard, including clarification on accounting for licenses of intellectual property and identifying performance obligations. This new standard specifically outlines that patents, underlying highly functional items, are considered functional IP. Licenses to functional IP are considered satisfied at a point in time and any resulting revenue is recognized at that point in time. The standard further indicates that “in very rare circumstances, if at all” can licenses to functional IP be recognized over time. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company currently anticipates adopting the standard using the full retrospective method to restate each prior reporting period presented effective beginning January 1, 2018. License agreements can generally be classified as either: (1) running royalty agreements in which licensees provide reports on their sales activities for the previous fiscal quarter, and calculate and remit the appropriate royalty; or (2) fixed fee arrangements with either a one-time lump sum payment or periodic payments that may be over a period shorter than or equal to the license term. The Company anticipates this standard will have a material impact on its consolidated financial statements. While the Company is continuing to assess all potential impacts of the standard, it currently believes the most significant impact relates to its accounting for fixed fee arrangement license agreements for functional IP that contain periodic payments that may be over a period shorter than or equal to the license term. The Company expects to recognize license revenue at a point in time, when the right to use the functional IP is granted which coincides with contract execution and the time of billing, rather than over the period of periodic payments. Due to the complexity of certain of these license agreements, the actual revenue recognition treatment required under the standard will be dependent on contract-specific terms, and may vary in some instances from recognition at the time of billing. The Company is also further evaluating the income tax impact of these changes in revenue recognition. In November 2015, the Financial Accounting Standards Board issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes". The amendments in this update eliminate the current requirement for companies to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Instead, companies will be required to classify all deferred tax liabilities and assets as non-current. The guidance is effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The guidance will not have an impact on the Company’s financial statements since deferred income taxes are already presented as long-term on the balance sheet. In February 2016, the Financial Accounting Standards Board issued ASU 2016-2, “Leases”. The amendments in this update would require companies and other organizations to include lease obligations in their balance sheets, including a dual approach for lessee accounting under which a lessee would account for leases as finance leases or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use (“ROU”) asset and a corresponding lease liability. For finance leases the lessee would recognize interest expense and amortization of the ROU asset, and for operating leases, the lessee would recognize a straight-line total lease expense. The guidance is effective for interim and annual periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently assessing the impact of this new standard. In March 2016, the Financial Accounting Standards Board issued ASU 2016-09, "Improvements to Employee Share-Based Payments Accounting". The amendments in this update address the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2016. The Company is currently assessing the impact of this new standard. In August 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update 2016-15, “Statement of Cash Flows (Topic 230)”, a consensus of the FASB’s Emerging Issues Task Force. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. For public business entities, the standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company is currently assessing the impact of this new standard.

Taxes

Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Taxes	3. TAXES The reconciliation of the expected provision for income tax expense to the actual provision for income tax expense reported in the consolidated statements of operations and comprehensive earnings for the years ended December 31, 2016 and 2015 is as follows: 2016 2015 Earnings before income taxes $ 19,622 $ 16,957 Expected income tax expense at Canadian statutory income tax rate of 26.5% (2015 - 26.5%) 5,200 4,494 Permanent differences 398 (800 ) Effect of change in tax rates - 154 Foreign withholding taxes paid 1,089 496 Foreign rate differential 158 (683 ) Increase in valuation allowance 1,725 3,260 Provision for income tax expense $ 8,570 $ 6,921 During the years ended December 31, 2016 and 2015, the reported earnings before income taxes includes foreign earnings of $542 and losses of $8,299, respectively. The significant components of the Company’s deferred income tax assets and liabilities as at December 31, 2016 and 2015 are as follows: 2016 2015 Tax loss carryforwards $ 24,096 $ 26,155 Scientific research and experimental development ("SR&ED") carryforwards 5,051 5,051 Investment tax credits 4,151 4,151 Accounts payable and accrued liabilities 489 1,291 Difference between tax and book value of patent finance obligations (153 ) (343 ) Difference between tax and book value of capital and intangible assets 306 (1,072 ) Difference between tax and book value of loan receivable 14 27 Total future income tax asset 33,954 35,260 Valuation allowance (19,308 ) (17,583 ) Net future income tax asset $ 14,646 $ 17,677 Management has assigned probabilities to the Company’s expected future taxable income based on significant risk factors, sensitivity analysis and timing of non-capital tax losses. The amount of the deferred income tax asset considered realizable could change materially in the near term, based on future taxable income during the carryforward period. The valuation allowance consists of $9,655 in Canada and $9,653 in the US. As at December 31, 2016, the Company had unused non-capital tax losses of approximately $71,999 (2015 - $77,647) that are due to expire as follows: SR&ED Expenditure Pool Canadian Tax Losses United States Tax Losses Consolidated Tax Losses 2030 $ - $ 1,146 $ - $ 1,146 2031 - 2,442 601 3,043 2032 - 4,458 2,084 6,542 2033 - 26,703 4,807 31,510 2034 - 4,276 7,629 11,905 2035 - 1,889 4,154 6,043 2036 - 11,810 - 11,810 Indefinite 19,061 - - - $ 19,061 $ 52,724 $ 19,275 $ 71,999 The Company also has investment tax credits of $5,647, that expire in various amounts from 2017 to 2032 and $22,068 of capital losses carried forward with no expiry date. Investment tax credits, which are earned as a result of qualifying SR&ED expenditures, are recognized and applied to reduce income tax expense in the year in which the expenditures are made and their realization is reasonably assured. The Company had no uncertain income tax positions for the years ended December 31, 2016 and 2015. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax provision. In the years ended December 31, 2016 and 2015, there were no interest or penalties included in the income tax provision. The Company files Canadian and U.S. federal and state income tax returns. The Company is subject to examination by the tax authorities for the tax years ended 2010 through 2015.

Loan Receivable

Loan Receivable	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Loan Receivable	4. LOAN RECEIVABLE On October 19, 2012 (the “Closing Date”), the Company advanced a term loan facility in the amount of $1,000 to Montebello Technologies LLC (the “Borrower”). The loan bears interest at 15% per annum, compounded annually with a maturity date of October 18, 2017 at which time the outstanding principal and accrued interest is to be fully repaid. The term loan facility is collateralized by a general security agreement. In accordance with the terms and conditions of the loan agreement the use of the funds is solely and exclusively for the purchase and monetization of patents and for the period commencing on the Closing Date to and including the tenth anniversary of the Closing Date, the Company will be entitled to receive (a) 15% of the first $10 million in gross revenue and (b) 10% of all gross revenue over the first $10 million realized by the Borrower from any patents acquired utilizing the term loan facility. To estimate the fair value, at inception, the Company considered the estimated future cash flow projections using an effective interest rate of 18%. The carrying value of the term loan facility is as follows: As As at December 31, 2016 2015 15% Term loan facility $ 1,000 $ 1,000 Unamortized discount (36 ) (70 ) Accrued interest 802 567 Net carrying amount $ 1,766 $ 1,497

Furniture and Equipment

Furniture and Equipment	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	5. PROPERTY AND EQUIPMENT Cost Accumulated Depreciation Net Book Value As at December 31, 2016 Leasehold improvements $ 1,373 $ 461 $ 912 Computer equipment and software 2,102 1,882 220 Furniture and equipment 496 388 108 $ 3,971 $ 2,731 $ 1,240 As at December 31, 2015 Leasehold improvements $ 1,373 $ 322 $ 1,051 Computer equipment and software 2,092 1,843 249 Furniture and equipment 872 558 314 $ 4,337 $ 2,723 $ 1,614 The Company purchased property and equipment totaling $48 during 2016 (2015 - $178). During 2016, the Company disposed of property and equipment with a cost and accumulated amortization totaling $414 and $401, respectively for no proceeds resulting in a loss on disposal of $13.

Patents

Patents	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Patents	6. PATENTS Cost Accumulated Amortization Net Book Value As at December 31, 2016 Patents $ 345,603 $ 222,252 $ 123,351 As at December 31, 2015 Patents $ 357,059 $ 201,846 $ 155,213 The Company purchased patents totaling $1,660 during 2016 (2015 - $46,973) and recorded amortization expense of $33,521 (2015 - $36,498). As at December 31, 2016, the estimated remaining economic useful lives of the patents range from one to thirteen years. In October 2015, the Company commenced a restructuring of its operations (see Note 13) and as a result undertook a review of its licensing programs to determine those which it would continue to support. The Company concluded that certain licensing programs would be terminated and the carrying value of the patent portfolios associated with these licensing programs were determined to be fully impaired. As a result, the Company recorded a non-cash, pre-tax charge against its patents of $1,747. The Company’s market valuation at December 31, 2016 net of its cash position was below the carrying value of its assets. Management deemed this to be an indicator of impairment and therefore a test for impairment of its long-lived assets was performed as at December 31, 2016 (the “Measurement Date”). The patents (“asset groups”) were categorized in accordance with their licensing programs. The Company performed the recoverability test using undiscounted cash flows of the asset groups based on the Company’s internal forecast for the period from January 1, 2017 through to December 31, 2023, and assumptions for each of the licensing programs. Based on this analysis, the Company concluded that the carrying value for the asset groups is recoverable, as the amount did not exceed the estimated undiscounted future cash flows as at the Measurement Date and therefore the second step of long-lived asset test impairment was not required. The estimated future amortization expense of patents as at December 31, 2016 is as follows: Year ending December 31: Amount 2017 $ 20,874 2018 17,941 2019 16,354 2020 15,302 2021 14,566 $ 85,037

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	7. GOODWILL The Company performed its annual impairment assessment as at December 31, 2016 by comparing the estimated fair value of the reporting unit, using an income based approach and market based approach, to its carrying value as at December 31, 2016. Under the income based approach, the Company used a discounted cash flow methodology. Under the market based approach, the Company considered its market capitalization in addition to an estimated control premium. The results of this impairment assessment indicated that the estimated fair value of the reporting unit exceeded it carrying amount, therefore, the Company concluded there was no impairment of goodwill.

Patent Finance Obligations

Patent Finance Obligations	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Patent Finance Obligations	8. PATENT FINANCE OBLIGATIONS On June 18, 2014, the Company acquired the right to license certain patents, the consideration for which is to be fully paid on or before June 18, 2023; however; the timing of the payments is subject to the Company entering into certain future license agreements with third-parties. The Company has set up the liability based on its expected payment schedule using a discount rate of 6.0%. The discount rate is an estimate of a risk-adjusted rate giving consideration to rates for revolving debt with no fixed payments. As at December 31, 2016, the current and long-term portions of this obligation are $5,129 and $8,685, respectively. On September 13, 2014, the Company acquired certain patents and entered into a licensing agreement with the same counter-party. The obligation was based on the quarterly payment stream of $1,389 using a discount rate of 4.5%. The discount rate is an estimate of a risk-adjusted rate giving consideration to rates for secured term debt with fixed payments over a five year term. As at December 31, 2016, the current and long-term portions of this obligation are $5,243 and $4,090, respectively. The current and long-term portions of these obligations are reflected as follows: Gross Unamortized Discount Net Carrying Amount As at December 31, 2016 Patent rights finance obligation, due June 18, 2023 $ 14,000 $ (185 ) $ 13,815 Patent finance obligation, due August 18, 2018 9,722 (390 ) 9,332 23,722 (575 ) 23,147 Current portion (10,372 ) $ 12,775 Gross Unamortized Discount Net Carrying Amount As at December 31, 2015 Patent rights finance obligation, due June 18, 2023 $ 14,000 $ (364 ) $ 13,636 Patent finance obligation, due August 18, 2018 15,277 (933 ) 14,344 29,277 (1,297 ) 27,980 Current portion (8,085 ) $ 19,895 Payments are expected to be as follows: 2017 10,556 2018 11,166 2019 2,000 $ 23,722

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Accounts Payable and Accrued Liabilities	9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As at December 31, As at December 31, 2016 2015 Trade payables $ 913 $ 1,318 Accrued compensation 6,099 3,146 Accrued litigation costs 151 2,363 Dividends 1,102 1,091 Success fee obligation - current portion 585 2,983 Accrued contingent partner payments & legal fees 4,077 1,140 Patent acquisition liability 1,000 9,000 Accrued other 1,718 2,164 $ 15,645 $ 23,205 The success fee obligation is pursuant to the Company’s engagement with a law firm, for which the firm is entitled to a percentage of proceeds actually received from certain license agreements signed by the Company related to certain litigation matters concluded in 2011 in which the firm was representing the Company. Should the Company collect these amounts as contemplated in the agreements, the firm will be entitled to the entire success fee of $27,986. During the year ended December 31, 2011, the Company accrued the full, undiscounted amount of the success fee obligation. The current and long term portion of this liability is reflected as follows: As at December 31, As at December 31, 2016 2015 Success fee obligation $ 632 $ 3,638 Current portion (585 ) (2,983 ) $ 47 $ 655

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Share Capital	10. SHARE CAPITAL a) Authorized Unlimited number of common shares. 6,350.9 special preferred, redeemable, retractable, non-voting shares. An unlimited number of preferred shares, issuable in series. b) Issued and Outstanding The issued and outstanding common shares of WiLAN, along with equity instruments convertible into common shares, are as follows: As As at December 31, 2016 2015 Common shares 118,572,181 120,842,448 Securities convertible into common shares Stock options 5,985,454 8,071,056 Deferred stock units (DSUs) 197,367 260,398 124,755,002 129,173,902 As at December 31, 2016, no preferred shares or special preferred shares were issued or outstanding. c) Common Shares Number Amount December 31, 2014 120,247,647 $ 426,037 Issued on exercise of stock options 625,201 1,269 Transfer from additional paid-in capital on exercise of options - 787 Issued on sale of shares under Employee Share Purchase Plan 94,600 131 Repurchased under normal course issuer bid (125,000 ) (443 ) December 31, 2015 120,842,448 $ 427,781 Issued on exercise of stock options 4,333 11 Transfer from additional paid-in capital on exercise of options - 6 Issued on sale of shares under Employee Share Purchase Plan 70,600 72 Conversion of deferred stock units to common shares 53,300 116 Repurchased under normal course issuer bid (2,398,500 ) (8,501 ) December 31, 2016 118,572,181 $ 419,485 The Company paid quarterly cash dividends as follows: 2016 2015 Per Share Total Per Share Total 1st Quarter Cdn $ 0.0125 US $ 1,091 Cdn $ 0.0500 US $ 5,183 2nd Quarter 0.0125 1,151 0.0525 5,005 3rd Quarter 0.0125 1,153 0.0525 5,077 4th Quarter 0.0125 1,132 0.0525 4,817 Cdn $ 0.0500 US $ 4,527 Cdn $ 0.2075 US $ 20,082 The Company declared quarterly dividends as follows: 2016 2015 1st Quarter Cdn $ 0.0125 Cdn $ 0.0525 2nd Quarter 0.0125 0.0525 3rd Quarter 0.0125 0.0525 4th Quarter 0.0125 0.0125 On February 10, 2016, the Company received regulatory approval to make a normal course issuer bid (“2016 NCIB”) through the facilities of the Toronto Stock Exchange. Under the 2016 NCIB, the Company is permitted to purchase up to 11,762,446 common shares. The NCIB commenced on February 12, 2016 and will expire on February 11, 2017. The Company repurchased 2,398,500 common shares under the NCIB during the year ended December 31, 2016 for a total cost of $4,225. On May 27, 2014, the Company received regulatory approval to make a normal course issuer bid (the “2014 NCIB”) through the facilities of the Toronto Stock Exchange. Under the 2014 NCIB, the Company was permitted to purchase up to 11,676,510 common shares. The 2014 NCIB commenced on May 29, 2014 and was completed on May 28, 2015. The Company repurchased 125,000 common shares under the 2014 NCIB during the twelve months ended December 31, 2015 for a total of $329. The Company records share repurchases as a reduction to shareholders’ equity. A portion of the purchase price of the repurchased shares is recorded as a decrease to additional paid-in capital when the price of the shares repurchased exceeds the average original price per share received from the issuance of Common Stock or an increase to additional paid-in capital when the prices of the shares repurchased is less than the average original price per share received from the issuance of Common Stock. During the year ended December 31, 2016, the cumulative price of the shares repurchased was less than the proceeds received from the issuance of the same number of shares. For the year ended December 31, 2016, $4,276 was recorded as an increase to additional paid-in capital. During the year ended December 31, 2015, the cumulative price of the shares repurchased was less than the proceeds received from the issuance of the same number of shares. For the year ended December 31, 2015, $114 was recorded as an increase to additional paid-in capital. d) Stock Options WiLAN has an Option Plan, a DSU plan, an Employee Stock Purchase Plan, and a RSU plan for its directors, employees and consultants. The current RSU plan calls for settlement only in cash. The Option Plan, the DSU plan and the Employee Stock Purchase Plan are considered “security based compensation arrangements” for the purposes of the TSX. The Company is authorized to issue up to an aggregate of 10% of its outstanding common shares under these “security based compensation arrangements”, with the common shares authorized for issuance under the DSU plan limited to 430,000 and under the Employee Purchase Plan limited to 800,000. The options vest at various times ranging from immediate vesting on grant to vesting over a three to four year period. Options generally have a six-year life. Option activity for the years ended December 31, 2016 and 2015 was as follows: Options Outstanding Exercisable Options Number of Options Price Range (Cdn) Weighted Average Exercise Price (Cdn) Number Weighted Average Exercise Price (Cdn) December 31, 2014 9,465,372 $ 1.42 $ 7.09 $ 4.63 6,760,992 $ 4.83 Granted - - - - Exercised (625,201 ) 2.53 2.53 2.53 Forfeited (769,115 ) 2.53 5.52 3.97 December 31, 2015 8,071,056 $ 1.42 $ 7.09 $ 4.86 7,062,972 $ 4.97 Granted 256,477 2.84 3.32 2.86 Exercised (4,333 ) 3.12 3.33 3.28 Forfeited (86,999 ) 3.49 4.37 3.84 Expired (2,250,747 ) 3.40 7.09 4.85 December 31, 2016 5,985,454 $ 2.84 $ 5.66 $ 4.78 5,617,312 $ 4.89 The Company uses the Black-Scholes model for estimating the fair value of options granted, with the following weighted average assumptions for the options granted in 2015: 2016 2015 Risk free interest rate 0.9 % NA Volatility 49 % NA Expected option life (in years) 5.6 NA Dividend yield 3.2 % NA Forfeiture rate 14.5 % NA The weighted average fair value per option granted during the year ended December 31, 2016 was CDN $0.98 (2015 – NA) The intrinsic value of options exercised was CDN $2 for the year ended December 31, 2016 (2015 – CDN $488). Intrinsic value is the total value of exercised options based on the price of the Company’s common shares at the time of the exercise less the proceeds received from the employees to exercise the options. The intrinsic value of the exercisable options was Nil as at December 31, 2016 (2015 –Nil). The total fair value of options vested was CDN $956 for the year ended December 31, 2016 (2015 – CDN $1,634). As at December 31, 2016, there was CDN $154 of total unrecognized stock-based compensation cost, net of expected forfeitures, related to unvested stock-based compensation arrangements granted under the stock option plan. This cost is expected to be recognized over a weighted average period of 2.17 years. Details of the outstanding options at December 31, 2016 are as follows: Range of Exercise Prices (Cdn) Outstanding Options at December 31, 2016 Remaining Term of Options in Years Weighted Average Exercise Price (Cdn) Exercisable Options at December 31, 2016 Weighted Average Exercise Price (Cdn) $ 2.84 $ 3.00 246,477 5.58 $ 2.84 - $ - 3.01 4.00 757,167 2.93 3.43 660,502 3.44 4.01 5.00 1,500,800 2.19 4.45 1,475,800 4.46 5.01 6.00 3,481,010 0.60 5.36 3,481,010 5.36 $ 2.84 $ 6.00 5,985,454 1.50 $ 4.78 5,617,312 $ 4.89 Stock-based compensation expense for the year ended December 31, 2016 was $217 (2015 - $847). The following provides a summary of the stock-based compensation expense for the years ended December 31, 2016 and 2015: 2016 2015 Cost of revenue $ 174 $ 460 Research and development - 81 Marketing, general and administration 43 306 $ 217 $ 847 e) Deferred Stock Units The Company has a Deferred Stock Unit (“DSU”) plan as a tool to assist in the retention of selected employees and directors and to help conserve the Company’s cash position. Under the DSU plan, DSUs may be awarded and will become due when the conditions of retention have been met and employment terminated or completed. The value of each DSU is determined in reference to the Company’s common share price, and the DSU value is payable in either cash or shares at the Company’s option. Number December 31, 2014 244,526 Issued in lieu of quarterly fees 5,000 Issued in lieu of dividends paid 10,872 Settled for cash - Settled for common shares - December 31, 2015 260,398 Issued in lieu of quarterly fees 21,936 Issued in lieu of dividends paid 14,690 Settled for cash (46,357 ) Settled for common shares (53,300 ) December 31, 2016 197,367 The liability recorded in respect of the outstanding DSUs was $322 as at December 31, 2016 (2015 - $367). The change in the liability is recorded as compensation expense. f) Restricted Share Units The Company implemented a Restricted Share Unit (“RSU”) plan for certain employees and directors in January 2007. Under the RSU plan, units are settled in cash based on the market value of WiLAN’s common shares on the dates when the RSUs vest. The accrued liability and related expense for the RSUs are adjusted to reflect the market value of the common shares at each balance sheet date. The liability recorded in respect of the vested RSUs was $1,348 as at December 31, 2016 (2015 - $684). The change in the liability is recorded as compensation expense. RSU activity for the years ended December 31, 2016 and 2015 was as follows: Number December 31, 2014 1,294,278 Granted 1,101,021 Settled (103,155 ) Forfeited (783,112 ) December 31, 2015 1,509,032 Granted 2,477,861 Settled (1,148,892 ) Forfeited (125,491 ) December 31, 2016 2,712,510 During the year ended December 31, 2016, 125,491 RSUs (2015 – 783,112) were forfeited as they related to former employees. g) Per Share Amounts The weighted average number of common shares outstanding used in the basic and diluted earnings per share (“EPS”) computation was: 2016 2015 Basic weighted average common shares outstanding 119,245,581 120,713,535 Effect of options - 6,636 Diluted weighted average common shares outstanding 119,245,581 120,720,171 The effect of options totaling 5,985,454 for fiscal 2016 (fiscal 2015 – 8,071,056), were anti-dilutive.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2016
Investments All Other Investments [Abstract]
Financial Instruments	11. FINANCIAL INSTRUMENTS The Company is exposed to a number of risks related to changes in foreign currency exchange rates, interest rates, collection of accounts receivable and loan receivable, settlement of liabilities and management of cash and cash equivalents. Fair Value The Company uses various valuation techniques and assumptions when measuring fair value of its assets and liabilities. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. The accounting standard establishes a hierarchy that prioritizes fair value measurements based on the types of input used for the various valuation techniques (market approach, income approach and cost approach). The levels of the hierarchy are described below: Level 1 Inputs — Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets. Level 2 Inputs — Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data, including market interest rate curves, referenced credit spreads and pre-payment rates. Level 3 Inputs — Level 3 includes financial instruments for which fair value is derived from valuation techniques including pricing models and discounted cash flow models in which one or more significant inputs are unobservable, including the company’s own assumptions. The pricing models incorporate transaction details such as contractual terms, maturity and, in certain instances, timing and amount of future cash flows, as well as assumptions related to liquidity and credit valuation adjustments of marketplace participants. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalent, and short-term investments: The carrying amount approximates fair value because of the short maturity of those instruments. Loan receivable: The fair value is estimated based on currently available market interest rates for instruments with similar terms. Patent finance obligations: The fair values are estimated based on the quoted market prices for those or similar instruments or on the current rates offered to the Company for debt of similar terms. The estimated fair values of the Company’s financial instruments are as follows: As at December 31, 2016 As at December 31, 2015 Hierarchy Level Carrying Amount Fair Value Carrying Amount Fair Value Cash and cash equivalents 1 $ 106,553 $ 106,553 $ 93,431 $ 93,431 Short-term investments 1 1,154 1,154 1,120 1,120 Loan receivable 2 1,766 1,766 1,497 1,497 Patent finance obligations 3 23,146 23,146 27,980 27,980 Credit risk Credit risk is the risk of financial loss to the Company if a licensee or counter-party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, loan receivable, and foreign exchange forward contracts. The Company’s cash and cash equivalents, and short-term investments consist primarily of deposit investments that are held only with Canadian chartered banks. Management does not expect any counter-parties to fail to meet their obligations. The Company’s loan receivable is a term loan facility which is collateralized by a general security agreement. Management does not expect the borrower to fail to meet its obligations. The Company’s exposure to credit risk with its accounts receivable from licensees is influenced mainly by the individual characteristics of each licensee. The Company’s licensees are for the most part, manufacturers and distributors of telecommunications and consumer electronics products primarily located in the United States, Canada, Taiwan, Korea, Japan, Hong Kong and China. Credit risk from accounts receivable encompasses the default risk of the Company’s licensees. Prior to entering into licensing agreements with new licensees the Company assesses the risk of default associated with the particular company. In addition, on an ongoing basis, management monitors the level of accounts receivable attributable to each licensee and the length of time taken for amounts to be settled and where necessary, takes appropriate action to follow up on those balances considered overdue. The Company has had no significant bad debts for any periods presented. Three licensees individually accounted for 18%, 14% and 11%, respectively of revenues for the year ended December 31, 2016 (for the year ended December 31, 2015 – three licensees individually accounted for 16%, 12 and 10%, respectively). Management does not believe that there is significant credit risk arising from any of the Company’s licensees for which revenue has been recognized. However, should one of the Company’s major licensees be unable to settle amounts due, the impact on the Company could be significant. The maximum exposure to loss arising from accounts receivable is equal to their total carrying amounts. At December 31, 2016, two licensees individually accounted for 80%, and 16% of total accounts receivable (December 31, 2015 – three licensees individually accounted for 47%, 15%, and 10% of total accounts receivable). Financial assets past due The following table provides information regarding the aging and collectability of the Company’s accounts receivable balances as at December 31, 2016: Current $ 20,311 Past due 1 - 30 days 19 Past due 31 - 60 days 7 Past due 61 - 90 days - Over 91 days past due 158 Less allowance for doubtful accounts (138 ) $ 20,357 The definition of items that are past due is determined by reference to terms agreed with individual licensees. As at January 31, 2017, Nil of past due amounts have been collected. None of the amounts outstanding have been challenged by the respective licensees and the Company continues to conduct business with them on an ongoing basis. Accordingly, management has no reason to believe that this balance is not fully collectable in the future. The Company reviews financial assets past due on an ongoing basis with the objective of identifying potential matters which could delay the collection of funds at an early stage. Once items are identified as being past due, contact is made with the respective company to determine the reason for the delay in payment and to establish an agreement to rectify the breach of contractual terms. At December 31, 2016, the Company had a provision for doubtful accounts of $138 (2015 - $11) which was made against accounts receivable where collection efforts to date have been unsuccessful. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective in managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. At December 31, 2016, the Company had cash and cash equivalents and short-term investments of $107,707, a credit facility of CDN$8,000 and accounts receivable of $20,357 available to meet its obligations. The Company has a revolving credit facility available in the amount of CDN$8,000 or the equivalent in U.S. dollars for general corporate purposes and a further CDN$2,000 for foreign exchange facility. Canadian dollar or U.S. dollar amounts advanced under this credit facility are payable on demand and bear interest at the bank's Canadian prime rate plus 1.0% per annum or U.S. base rate plus 1.0% per annum. Borrowings under this facility are collateralized by a general security agreement over our cash and cash equivalents, accounts receivable and present and future personal property. As at and during the twelve months ended December 31, 2016, the Company had no borrowings under this facility. Market risk Market risk is the risk to the Company that the fair value of future cash flows from its financial instruments will fluctuate due to changes in interest rates and foreign currency exchange rates. Market risk arises as a result of the Company generating revenues in foreign currencies. Interest rate risk The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents and short-term investments. The Company’s objectives of managing its cash and cash equivalents and short-term investments are to ensure sufficient funds are maintained on hand at all times to meet day to day requirements and to place any amounts which are considered in excess of day to day requirements on short-term deposit with the Company’s banks so that they earn interest. When placing amounts of cash and cash equivalents into short-term investments, the Company only places investments with Canadian chartered banks and ensures that access to the amounts placed can be obtained on short-notice. A one percent increase/decrease in interest rates could have resulted in an approximate increase/decrease to interest income of $1,077. Currency risk A portion of WiLAN’s revenues and operating expenses are denominated in Canadian dollars. Because the Company reports its results of operations in US dollars, WiLAN’s operating results are subject to changes in the exchange rate of the Canadian dollar relative to the US dollar. Any decrease in the value of the Canadian dollar relative to the US dollar has an unfavourable impact on Canadian dollar denominated revenues and a favourable impact on Canadian dollar denominated operating expenses. Approximately 5% of the Company’s cash and cash equivalents and short term investments are denominated in Canadian dollars and are subject to changes in the exchange rate of the Canadian dollar relative to the US dollar. For the year ended December 31, 2016, the Company had revenues and expenses denominated in Canadian dollars of approximately Nil and $14,019 (2015 – Nil and $17,912), respectively. Fluctuations in foreign currency rates between the U.S. and Canadian dollars could impact the net exposure approximating $14,019 (2015 - $17,912) and adversely affect net earnings of the Company. At December 31, 2016, the Company had Canadian dollar denominated cash and cash equivalents and short-term investments, and accounts receivable balances of approximately $5,235 and Nil (2015 - $5,394 and $3), respectively, offset by accounts payable and accrued liabilities totaling approximately $9,108 (2015 - $5,047). Fluctuations in foreign currency rates between the U.S. and Canadian dollars could impact the net exposure approximating $3,873 (2015 - $349) and adversely affect net earnings of the Company. A ten cent increase/decrease in foreign currency rates between the U.S. and Canadian dollars could have resulted in an approximate increase/decrease to net and comprehensive earnings of $1,144. (2015 - $30) The Company may manage the risk associated with foreign exchange rate fluctuations by, from time to time, entering into foreign exchange forward contracts and engaging in other hedging strategies. To the extent that WiLAN engages in risk management activities related to foreign exchange rates, it may be subject to credit risks associated with the counterparties with whom it contracts. The Company’s objective in obtaining foreign exchange forward contracts is to manage its risk and exposure to currency rate fluctuations related primarily to future cash inflows and outflows of Canadian dollars. The Company does not use foreign exchange forward contracts for speculative or trading purposes. For the year, and as at December 31, 2016, the Company did not hold any foreign exchange forward contracts

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. COMMITMENTS AND CONTINGENCIES a) Operating lease The Company has lease agreements for office space and equipment with terms extending to 2023. The aggregate minimum annual lease payments under these agreements are as follows: Amount 2017 $ 652 2018 $ 568 2019 $ 497 2020 $ 358 2021 and thereafter $ 1,075 $ 3,150 b) Other In connection with the acquisition of certain patents and patent rights, the Company has agreed to future additional payments to the former owners of the respective patents or patent rights, based on future revenues (as defined in the respective agreements) generated as a result of licensing the respective patents or patent portfolios. For the year ended December 31, 2016, partner royalties totaled $832 (year ended December 31, 2015 – $669) of which $121 (as at December 31, 2015 - $538) remains outstanding as at December 31, 2016. On December 16, 2013, the Company engaged the services of an external law firm to represent the Company in certain patent infringement litigations. Pursuant to this engagement, in consideration for a discounted fixed fee arrangement, the Company has agreed to pay the firm a success fee which is based on a percentage of proceeds received (as defined in the respective agreements) pursuant to future license agreements resulting from these patent infringement litigations. As at December 31, 2016, the success fees are not yet determinable because the total proceeds have not yet been determined and therefore no amounts have been accrued.

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Restructuring Charges	13. RESTRUCTURING CHARGES In October 2015, the Company undertook a restructuring plan which included a workforce reduction of approximately 30%. The components of the restructuring charge included $1,272 for termination costs related to the affected employees, and $30 for lease obligations. The following table summarizes the details of the Company’s restructuring charges and related reserves: Workforce Reduction Lease Obligation Total Charges $ 1,272 $ 30 $ 1,302 Cash payments ( 760 ) ( 9 ) ( 769 ) Balance of provision as at December 31, 2015 512 21 533 Charges - - - Cash payments (512 ) (21 ) (533 ) Balance of provision as at December 31, 2016 $ - $ - $ -

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	14. SUPPLEMENTAL CASH FLOW INFORMATION 2016 2015 Net interest received in cash, included in operations $ (206 ) $ (207 ) Taxes paid 5,699 3,623 Patent acquisition liability 1,000 9,000

Related-Party Transaction

Related-Party Transaction	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related-Party Transaction	15. RELATED-PARTY TRANSACTION Dr. Michel Fattouche, a member of the Company’s Board of Directors, has provided consulting services to the Company. For the year ended December 31, 2016, consulting services have totaled $8 (year ended December 31, 2015 – $100) all of which had been paid as at year end.

Significant Accounting Polici21

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements of WiLAN include the accounts of WiLAN and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in the consolidated financial statements.
Estimates and Assumptions	Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the years. Actual results could differ from those estimates. The significant accounting policies contained herein include estimates and assumptions with respect to best estimate of selling price, determination of discount rates, recoverability of deferred tax assets, determination of indicators of impairment assessment and related impairment assessments, initial estimate of risk of concessions, timing of payments related to patent finance obligations, and the assumptions used in determining the fair value of stock options granted.
Revenue Recognition	Revenue Recognition The Company’s revenue consists principally of royalty revenue from licensing its own patent portfolio. The Company may also generate royalty revenue from licensing patent portfolios on behalf of its partners. The Company considers revenue to be earned when it has persuasive evidence of an arrangement, the obligation has been fulfilled in accordance with the terms of the licensing agreement, including delivery and acceptance, the amounts are fixed or determinable and collection is reasonably assured. The Company defers recognizing revenue until such time as all criteria are met. Determination of whether or not these criteria have been met may require the Company to make judgments, assumptions and estimates based upon current information and historical experience. The Company’s revenues consist of fixed fee and running royalty payments. Revenues from running royalty arrangements can be based on either a percentage of sales or number of units sold for which the Company earns revenues at the time the licensees’ sales occur. The licensees are obligated to provide the Company with quarterly or semi-annual royalty reports and these reports are typically received subsequent to the period in which the licensees underlying sales occurred. The Company’s licensees do not, however, report and pay royalties owed for sales in any given reporting period until after the conclusion of that reporting period. As the Company is unable to estimate the licensees’ sales in any given reporting period to determine the royalties due to it, the Company recognizes running royalty revenues based on royalties reported by the licensees during the quarter and when other revenue recognition criteria are met. The Company monitors the receipt of royalty reports to ensure that there is not a disproportionate number of months of revenue in any given fiscal year. Revenues from fixed fee royalty arrangements may consist of one or more installments of cash. The timing and amount of revenue recognized from each licensee depends upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Where agreements include multiple elements, the Company assesses if the deliverables have standalone value upon delivery, and if so, accounts for each deliverable separately. When multiple-deliverables included in an arrangement are separated into different units of accounting, the arrangement consideration is allocated to the identified separate units based on a relative selling price hierarchy. WiLAN determines the relative selling price for a deliverable based on its best estimate of selling price (“BESP”). WiLAN determines BESP by considering its overall pricing objectives and market conditions. Significant pricing practices taken into consideration include discounting practices, the size and volume of transactions, the customer demographic, the geographic area covered by licenses, price lists, licensing strategy, historical standalone licenses and contracted royalty rates. The determination of BESP is made through consultation with and approval by management, taking into consideration the licensing strategy. As part of the partnering agreements with third parties, the Company is able to recover certain out-of-pocket expenses and legal costs. These amounts are included in revenue in the years which the aforementioned revenue criteria is met and the amounts become reimbursable. Revenue arrangements with extended payment terms, where fees are fixed in one or more installments of cash and which contain terms that could impact the amounts ultimately collected, are generally recognized as collection becomes assured.
Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes. Deferred income tax assets and liabilities are determined based on the difference between the accounting and tax bases of the assets and liabilities and measured using the enacted tax rates that are expected to be in effect when the differences are estimated to be reversed. In assessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of deferred income tax assets is dependent upon the generation of sufficient future taxable income during the periods prior to the expiration of the associated tax attributes.
Cost of Revenue	Cost of Revenue Cost of revenue includes patent licensing expenses, royalty obligations, staff costs (including stock-based compensation) and other costs incurred in conducting license negotiations as well as litigation, the expenses related to the management of the patent portfolio, contingent partner payments and legal fees and amortization expense related to acquired patents, which are expensed as incurred.
Research and Development ("R&D")	Research and Development (“R&D”) R&D includes engineering expenses, staff costs (including stock-based compensation) and certain external consultants related to the development efforts, which were expensed as incurred.
Computation of Earnings (Loss) Per Share	Computation of Earnings (Loss) Per Share Basic earnings/loss per share is computed using the weighted average number of common shares outstanding during the year. Diluted earnings/loss per share is computed using the treasury stock method.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional currency is the U.S. dollar; monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars at exchange rates prevailing at the balance sheet date. Revenue and expenses are translated at the average rate for the period. The gains and losses from foreign currency denominated transactions are included in foreign exchange gain/loss in the consolidated statement of operations and comprehensive earnings. The Company enters into foreign exchange forward contracts, from time to time, to manage its exposure to currency rate fluctuations related primarily to future cash inflows and outflows of Canadian dollars. The Company does not hold or issue derivative financial instruments for trading or speculative purposes and it has chosen not to designate them as hedges. Therefore these contracts must be fair valued each quarter. The resulting gain or loss on the valuation of these financial instruments is included in foreign exchange gain/loss in the consolidated statement of operations and comprehensive earnings.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents comprise cash in bank accounts, term deposits and Guaranteed Investment Certificates (“GICs”) with original maturities of three months or less at the date of the investment.
Short Term Investments	Short-term Investments Short-term investments are designated as “held to maturity” and accounted for at amortized cost using the effective interest rate method. Short-term investments comprise GICs with original maturities of one-year or less at the date of investment and their carrying value approximates their fair value.
Loan Receivable	Loan Receivable The loan receivable is accounted for at amortized cost using the effective interest rate method.
Property and Equipment	Property and Equipment Furniture and equipment is carried at cost less accumulated depreciation. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets as follows: Leasehold improvements term of the lease Computer equipment and software 3 years Furniture and equipment 5 years
Patents	Patents Patents include patents and patent rights (hereinafter, collectively “patents”) and are carried at cost less accumulated amortization. Amortization is calculated on the straight-line basis over the estimated useful life or the remaining term of the patent (up to 20 years), whichever is less.
Impairment of Long-Lived Assets	Impairment of long-lived assets The Company reviews long-lived assets ("LLA") such as property and equipment and patent asset groups for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. These events and circumstances may include significant decreases in the market price of an asset or asset group, significant changes in the extent or manner in which an asset or asset group is being used by the Company or in its physical condition, a significant change in legal factors or in the business climate, a history or forecast of future operating or cash flow losses, significant disposal activity, a significant decline in the Company's share price, a significant decline in revenues or adverse changes in the economic environment. When significant indicators of impairment exist, LLA impairment is tested using a two-step process. The Company performs a cash flow recoverability test as the first step, which involves comparing the estimated undiscounted future cash flows for the asset group to the carrying amount of the asset group. If the net cash flows of the asset group exceed its carrying amount, the asset group is not considered to be impaired. If the carrying amount of the asset group exceeds the net cash flows, there is an indication of potential impairment and the second step of the LLA impairment test is performed to measure the impairment amount. The second step involves determining the fair value of the asset group. Fair value is determined using valuation techniques that are in accordance with U.S. GAAP, including the market approach, income approach and cost approach. If the carrying amount of the asset group exceeds its fair value, then the excess represents the maximum amount of potential impairment that will be allocated to the asset group, with the limitation that the carrying value of each asset cannot be reduced to a value lower than that of its fair value. The total impairment amount allocated is recognized as a non-cash impairment loss.
Goodwill	Goodwill Goodwill is recorded as at the date of the business combination and represents the excess of the purchase price of acquired businesses over the fair value assigned to identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at year end or more frequently if events or changes in circumstances indicate the asset might be impaired. The impairment test is carried out in two steps. In the first step, the carrying value of the reporting unit including goodwill is compared with its fair value. When the fair value of a reporting unit exceeds its carrying value, goodwill of the reporting unit is considered not to be impaired and the second step is unnecessary. The Company has one reporting unit. In the event the fair value of the reporting unit, including goodwill, is less than the carrying value, the implied fair value of the reporting unit’s goodwill is compared with its carrying value to measure the amount of any impairment loss. When the carrying value of goodwill in the reporting unit exceeds the implied fair value of the goodwill, an impairment loss is recognized in an amount equal to the excess.
Patent Finance Obligations	Patent Finance Obligations Patent finance obligations have maturities beyond one year. Patent finance obligations, at inception, are recorded at their fair value using an estimated risk-adjusted discount rate and the carrying value is at amortized cost using the effective interest rate method.
Business Segment Information	Business Segment Information The Company has one operating segment and one reportable segment; Intellectual Property. The Company generates the majority of its revenues in U.S. dollars from several geographic regions; however it has allocated its revenues to the location in which the license originated. Substantially all licenses and revenue are attributable to Canada, as are long-lived assets.
Future accounting pronouncements	Future accounting pronouncements In May 2014, the Financial Accounting Standards Board issued ASU 2014-9, "Revenue from Contracts with Customers". The amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs-Contracts with Customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, "Revenue from Contracts with Customers" which reflects decisions reached by the Financial Accounting Standards Board at its meeting earlier in the year to defer the effective date to fiscal years beginning after December 15, 2017, with early adoption permitted. Under this new standard, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has issued several amendments to the standard, including clarification on accounting for licenses of intellectual property and identifying performance obligations. This new standard specifically outlines that patents, underlying highly functional items, are considered functional IP. Licenses to functional IP are considered satisfied at a point in time and any resulting revenue is recognized at that point in time. The standard further indicates that “in very rare circumstances, if at all” can licenses to functional IP be recognized over time. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company currently anticipates adopting the standard using the full retrospective method to restate each prior reporting period presented effective beginning January 1, 2018. License agreements can generally be classified as either: (1) running royalty agreements in which licensees provide reports on their sales activities for the previous fiscal quarter, and calculate and remit the appropriate royalty; or (2) fixed fee arrangements with either a one-time lump sum payment or periodic payments that may be over a period shorter than or equal to the license term. The Company anticipates this standard will have a material impact on its consolidated financial statements. While the Company is continuing to assess all potential impacts of the standard, it currently believes the most significant impact relates to its accounting for fixed fee arrangement license agreements for functional IP that contain periodic payments that may be over a period shorter than or equal to the license term. The Company expects to recognize license revenue at a point in time, when the right to use the functional IP is granted which coincides with contract execution and the time of billing, rather than over the period of periodic payments. Due to the complexity of certain of these license agreements, the actual revenue recognition treatment required under the standard will be dependent on contract-specific terms, and may vary in some instances from recognition at the time of billing. The Company is also further evaluating the income tax impact of these changes in revenue recognition. In November 2015, the Financial Accounting Standards Board issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes". The amendments in this update eliminate the current requirement for companies to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Instead, companies will be required to classify all deferred tax liabilities and assets as non-current. The guidance is effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The guidance will not have an impact on the Company’s financial statements since deferred income taxes are already presented as long-term on the balance sheet. In February 2016, the Financial Accounting Standards Board issued ASU 2016-2, “Leases”. The amendments in this update would require companies and other organizations to include lease obligations in their balance sheets, including a dual approach for lessee accounting under which a lessee would account for leases as finance leases or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use (“ROU”) asset and a corresponding lease liability. For finance leases the lessee would recognize interest expense and amortization of the ROU asset, and for operating leases, the lessee would recognize a straight-line total lease expense. The guidance is effective for interim and annual periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently assessing the impact of this new standard. In March 2016, the Financial Accounting Standards Board issued ASU 2016-09, "Improvements to Employee Share-Based Payments Accounting". The amendments in this update address the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2016. The Company is currently assessing the impact of this new standard. In August 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update 2016-15, “Statement of Cash Flows (Topic 230)”, a consensus of the FASB’s Emerging Issues Task Force. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. For public business entities, the standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company is currently assessing the impact of this new standard.
Employee Stock Option [Member]
Stock-based Compensation	Stock-based Compensation The Company has a share option plan (“Option Plan”) for certain employees, directors and consultants. The Company accounts for stock options using the fair value method. Compensation expense is measured at the estimated fair value of the options at the date of grant and charged to earnings on a straight-line basis over the vesting periods. The amount expensed is credited to additional paid-in capital in the period. Upon the exercise of stock options, cash received is credited to share capital together with any amount previously credited to additional paid-in capital related to the options exercised.
Deferred Stock Units (DSUs) [Member]
Stock-based Compensation	Deferred Stock Units (“DSUs” ) The Company has a DSU plan for certain employees and directors. The DSUs vest immediately and the Company has the right to settle the DSUs in either cash or by the issuance of common shares. The liability for outstanding units and related expense for the DSUs are adjusted to reflect the market value of the common shares at each balance sheet date.
Restricted Share Units (RSUs) [Member]
Stock-based Compensation	Restricted Share Units (“RSUs”) The Company has a RSU plan for certain employees and directors. Under the RSU plan, units are settled in cash based on the market value of WiLAN’s common shares on dates the RSUs vest. The RSUs vest over a three-year period. The accrued liability and related expense for the RSUs are adjusted to reflect the market value of the common shares at each balance sheet date.

Significant Accounting Polici22

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Depreciation is Calculated on Straight-Line Basis Over Estimated Useful Lives of Assets	Furniture and equipment is carried at cost less accumulated depreciation. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets as follows: Leasehold improvements term of the lease Computer equipment and software 3 years Furniture and equipment 5 years

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Reconciliation of Expected Provision for Income Tax Expense	The reconciliation of the expected provision for income tax expense to the actual provision for income tax expense reported in the consolidated statements of operations and comprehensive earnings for the years ended December 31, 2016 and 2015 is as follows: 2016 2015 Earnings before income taxes $ 19,622 $ 16,957 Expected income tax expense at Canadian statutory income tax rate of 26.5% (2015 - 26.5%) 5,200 4,494 Permanent differences 398 (800 ) Effect of change in tax rates - 154 Foreign withholding taxes paid 1,089 496 Foreign rate differential 158 (683 ) Increase in valuation allowance 1,725 3,260 Provision for income tax expense $ 8,570 $ 6,921
Significant Components of Future Income Tax Assets and Liabilities	The significant components of the Company’s deferred income tax assets and liabilities as at December 31, 2016 and 2015 are as follows: 2016 2015 Tax loss carryforwards $ 24,096 $ 26,155 Scientific research and experimental development ("SR&ED") carryforwards 5,051 5,051 Investment tax credits 4,151 4,151 Accounts payable and accrued liabilities 489 1,291 Difference between tax and book value of patent finance obligations (153 ) (343 ) Difference between tax and book value of capital and intangible assets 306 (1,072 ) Difference between tax and book value of loan receivable 14 27 Total future income tax asset 33,954 35,260 Valuation allowance (19,308 ) (17,583 ) Net future income tax asset $ 14,646 $ 17,677
Summary of Tax Losses and Scientific Research and Experimental Development Expenditure	As at December 31, 2016, the Company had unused non-capital tax losses of approximately $71,999 (2015 - $77,647) that are due to expire as follows: SR&ED Expenditure Pool Canadian Tax Losses United States Tax Losses Consolidated Tax Losses 2030 $ - $ 1,146 $ - $ 1,146 2031 - 2,442 601 3,043 2032 - 4,458 2,084 6,542 2033 - 26,703 4,807 31,510 2034 - 4,276 7,629 11,905 2035 - 1,889 4,154 6,043 2036 - 11,810 - 11,810 Indefinite 19,061 - - - $ 19,061 $ 52,724 $ 19,275 $ 71,999

Loan Receivable (Tables)

Loan Receivable (Tables)	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Carrying Value of Term Loan Facility	The carrying value of the term loan facility is as follows: As As at December 31, 2016 2015 15% Term loan facility $ 1,000 $ 1,000 Unamortized discount (36 ) (70 ) Accrued interest 802 567 Net carrying amount $ 1,766 $ 1,497

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Cost Accumulated Depreciation Net Book Value As at December 31, 2016 Leasehold improvements $ 1,373 $ 461 $ 912 Computer equipment and software 2,102 1,882 220 Furniture and equipment 496 388 108 $ 3,971 $ 2,731 $ 1,240 As at December 31, 2015 Leasehold improvements $ 1,373 $ 322 $ 1,051 Computer equipment and software 2,092 1,843 249 Furniture and equipment 872 558 314 $ 4,337 $ 2,723 $ 1,614

Patents (Tables)

Patents (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Patents	Cost Accumulated Amortization Net Book Value As at December 31, 2016 Patents $ 345,603 $ 222,252 $ 123,351 As at December 31, 2015 Patents $ 357,059 $ 201,846 $ 155,213
Estimated Future Amortization Expense of Patents	The estimated future amortization expense of patents as at December 31, 2016 is as follows: Year ending December 31: Amount 2017 $ 20,874 2018 17,941 2019 16,354 2020 15,302 2021 14,566 $ 85,037

Patent Finance Obligations (Tab

Patent Finance Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Current and Long-Term Portions of Obligations	The current and long-term portions of these obligations are reflected as follows: Gross Unamortized Discount Net Carrying Amount As at December 31, 2016 Patent rights finance obligation, due June 18, 2023 $ 14,000 $ (185 ) $ 13,815 Patent finance obligation, due August 18, 2018 9,722 (390 ) 9,332 23,722 (575 ) 23,147 Current portion (10,372 ) $ 12,775 Gross Unamortized Discount Net Carrying Amount As at December 31, 2015 Patent rights finance obligation, due June 18, 2023 $ 14,000 $ (364 ) $ 13,636 Patent finance obligation, due August 18, 2018 15,277 (933 ) 14,344 29,277 (1,297 ) 27,980 Current portion (8,085 ) $ 19,895
Schedule of Payments Expected	Payments are expected to be as follows: 2017 10,556 2018 11,166 2019 2,000 $ 23,722

Accounts Payable and Accrued 28

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As at December 31, As at December 31, 2016 2015 Trade payables $ 913 $ 1,318 Accrued compensation 6,099 3,146 Accrued litigation costs 151 2,363 Dividends 1,102 1,091 Success fee obligation - current portion 585 2,983 Accrued contingent partner payments & legal fees 4,077 1,140 Patent acquisition liability 1,000 9,000 Accrued other 1,718 2,164 $ 15,645 $ 23,205
Schedule of Current and Long Term Liability	The current and long term portion of this liability is reflected as follows: As at December 31, As at December 31, 2016 2015 Success fee obligation $ 632 $ 3,638 Current portion (585 ) (2,983 ) $ 47 $ 655

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Components of Common Shares Issued and Outstanding	The issued and outstanding common shares of WiLAN, along with equity instruments convertible into common shares, are as follows: As As at December 31, 2016 2015 Common shares 118,572,181 120,842,448 Securities convertible into common shares Stock options 5,985,454 8,071,056 Deferred stock units (DSUs) 197,367 260,398 124,755,002 129,173,902
Schedule of Common Stock	Number Amount December 31, 2014 120,247,647 $ 426,037 Issued on exercise of stock options 625,201 1,269 Transfer from additional paid-in capital on exercise of options - 787 Issued on sale of shares under Employee Share Purchase Plan 94,600 131 Repurchased under normal course issuer bid (125,000 ) (443 ) December 31, 2015 120,842,448 $ 427,781 Issued on exercise of stock options 4,333 11 Transfer from additional paid-in capital on exercise of options - 6 Issued on sale of shares under Employee Share Purchase Plan 70,600 72 Conversion of deferred stock units to common shares 53,300 116 Repurchased under normal course issuer bid (2,398,500 ) (8,501 ) December 31, 2016 118,572,181 $ 419,485
Schedule of Quarterly Cash Dividends Paid	The Company paid quarterly cash dividends as follows: 2016 2015 Per Share Total Per Share Total 1st Quarter Cdn $ 0.0125 US $ 1,091 Cdn $ 0.0500 US $ 5,183 2nd Quarter 0.0125 1,151 0.0525 5,005 3rd Quarter 0.0125 1,153 0.0525 5,077 4th Quarter 0.0125 1,132 0.0525 4,817 Cdn $ 0.0500 US $ 4,527 Cdn $ 0.2075 US $ 20,082
Schedule of Declared Quarterly Dividends	The Company declared quarterly dividends as follows: 2016 2015 1st Quarter Cdn $ 0.0125 Cdn $ 0.0525 2nd Quarter 0.0125 0.0525 3rd Quarter 0.0125 0.0525 4th Quarter 0.0125 0.0125
Schedule of Option Activity	Option activity for the years ended December 31, 2016 and 2015 was as follows: Options Outstanding Exercisable Options Number of Options Price Range (Cdn) Weighted Average Exercise Price (Cdn) Number Weighted Average Exercise Price (Cdn) December 31, 2014 9,465,372 $ 1.42 $ 7.09 $ 4.63 6,760,992 $ 4.83 Granted - - - - Exercised (625,201 ) 2.53 2.53 2.53 Forfeited (769,115 ) 2.53 5.52 3.97 December 31, 2015 8,071,056 $ 1.42 $ 7.09 $ 4.86 7,062,972 $ 4.97 Granted 256,477 2.84 3.32 2.86 Exercised (4,333 ) 3.12 3.33 3.28 Forfeited (86,999 ) 3.49 4.37 3.84 Expired (2,250,747 ) 3.40 7.09 4.85 December 31, 2016 5,985,454 $ 2.84 $ 5.66 $ 4.78 5,617,312 $ 4.89
Estimated Fair Value of Options Granted, Weighted Average Assumptions	The Company uses the Black-Scholes model for estimating the fair value of options granted, with the following weighted average assumptions for the options granted in 2015: 2016 2015 Risk free interest rate 0.9 % NA Volatility 49 % NA Expected option life (in years) 5.6 NA Dividend yield 3.2 % NA Forfeiture rate 14.5 % NA
Details of Outstanding Options	Details of the outstanding options at December 31, 2016 are as follows: Range of Exercise Prices (Cdn) Outstanding Options at December 31, 2016 Remaining Term of Options in Years Weighted Average Exercise Price (Cdn) Exercisable Options at December 31, 2016 Weighted Average Exercise Price (Cdn) $ 2.84 $ 3.00 246,477 5.58 $ 2.84 - $ - 3.01 4.00 757,167 2.93 3.43 660,502 3.44 4.01 5.00 1,500,800 2.19 4.45 1,475,800 4.46 5.01 6.00 3,481,010 0.60 5.36 3,481,010 5.36 $ 2.84 $ 6.00 5,985,454 1.50 $ 4.78 5,617,312 $ 4.89
Summary of Stock-Based Compensation Expense	The following provides a summary of the stock-based compensation expense for the years ended December 31, 2016 and 2015: 2016 2015 Cost of revenue $ 174 $ 460 Research and development - 81 Marketing, general and administration 43 306 $ 217 $ 847
Summary of Deferred Stock Units	The value of each DSU is determined in reference to the Company’s common share price, and the DSU value is payable in either cash or shares at the Company’s option. Number December 31, 2014 244,526 Issued in lieu of quarterly fees 5,000 Issued in lieu of dividends paid 10,872 Settled for cash - Settled for common shares - December 31, 2015 260,398 Issued in lieu of quarterly fees 21,936 Issued in lieu of dividends paid 14,690 Settled for cash (46,357 ) Settled for common shares (53,300 ) December 31, 2016 197,367
Summary of Restricted Stock Unit Activity	RSU activity for the years ended December 31, 2016 and 2015 was as follows: Number December 31, 2014 1,294,278 Granted 1,101,021 Settled (103,155 ) Forfeited (783,112 ) December 31, 2015 1,509,032 Granted 2,477,861 Settled (1,148,892 ) Forfeited (125,491 ) December 31, 2016 2,712,510
Weighted Average Number of Common Shares Outstanding Used in Basic and Diluted Earnings per Share Computation	The weighted average number of common shares outstanding used in the basic and diluted earnings per share (“EPS”) computation was: 2016 2015 Basic weighted average common shares outstanding 119,245,581 120,713,535 Effect of options - 6,636 Diluted weighted average common shares outstanding 119,245,581 120,720,171

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Investments All Other Investments [Abstract]
Summary of Estimated Fair Values of Entity's Financial Instruments	The estimated fair values of the Company’s financial instruments are as follows: As at December 31, 2016 As at December 31, 2015 Hierarchy Level Carrying Amount Fair Value Carrying Amount Fair Value Cash and cash equivalents 1 $ 106,553 $ 106,553 $ 93,431 $ 93,431 Short-term investments 1 1,154 1,154 1,120 1,120 Loan receivable 2 1,766 1,766 1,497 1,497 Patent finance obligations 3 23,146 23,146 27,980 27,980
Information Regarding Aging and Collectability of Accounts Receivable	The following table provides information regarding the aging and collectability of the Company’s accounts receivable balances as at December 31, 2016: Current $ 20,311 Past due 1 - 30 days 19 Past due 31 - 60 days 7 Past due 61 - 90 days - Over 91 days past due 158 Less allowance for doubtful accounts (138 ) $ 20,357

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of Aggregate Minimum Annual Lease Payments under Operating Lease	The Company has lease agreements for office space and equipment with terms extending to 2023. The aggregate minimum annual lease payments under these agreements are as follows: Amount 2017 $ 652 2018 $ 568 2019 $ 497 2020 $ 358 2021 and thereafter $ 1,075 $ 3,150

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Summary of Restructuring Charges and Related Reserves	The following table summarizes the details of the Company’s restructuring charges and related reserves: Workforce Reduction Lease Obligation Total Charges $ 1,272 $ 30 $ 1,302 Cash payments ( 760 ) ( 9 ) ( 769 ) Balance of provision as at December 31, 2015 512 21 533 Charges - - - Cash payments (512 ) (21 ) (533 ) Balance of provision as at December 31, 2016 $ - $ - $ -

Supplemental Cash Flow Inform33

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Summary of Supplemental Cash Flow Information	2016 2015 Net interest received in cash, included in operations $ (206 ) $ (207 ) Taxes paid 5,699 3,623 Patent acquisition liability 1,000 9,000

Significant Accounting Polici34

Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016Reporting_UnitSegments
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturities	Three months or less at the date of the investment.
Short-term investments comprise GICs with maturities	One year or less at the date of investment
Number of reporting unit | Reporting_Unit	1
Patent finance obligations, maturity	Beyond one year
Number of operating segment | Segments	1
Patents [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	20 years
Restricted Stock Units (RSUs) [Member]
Summary Of Significant Accounting Policies [Line Items]
RSUs vesting period	3 years

Significant Accounting Polici35

Significant Accounting Policies - Depreciation is Calculated on Straight-Line Basis Over Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2016
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	term of the lease
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	3 years
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	5 years

Taxes - Reconciliation of Expec

Taxes - Reconciliation of Expected Provision for Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Earnings before income taxes	$ 19,622	$ 16,957
Expected income tax expense at Canadian statutory income tax rate of 26.5% (2015 - 26.5%)	5,200	4,494
Permanent differences	398	(800)
Effect of change in tax rates		154
Foreign withholding taxes paid	1,089	496
Foreign rate differential	158	(683)
Increase in valuation allowance	1,725	3,260
Provision for income tax recovery	$ 8,570	$ 6,921

Taxes - Reconciliation of Exp37

Taxes - Reconciliation of Expected Provision for Income Tax Expense (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Canadian statutory income tax rate	26.50%	26.50%

Taxes - Additional Information

Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Examination [Line Items]
Foreign earnings and losses included in earnings before income tax	$ 542	$ (8,299)
Valuation allowance	19,308	17,583
Unused non-capital tax losses	71,999	77,647
Investment tax credits	$ 5,647
Tax credits expiration period	2017 to 2032
Capital losses carried forward	$ 22,068
Income tax provision, interest or penalties	0	$ 0
Canada [Member]
Income Tax Examination [Line Items]
Valuation allowance	9,655
Unused non-capital tax losses	52,724
U.S. [Member]
Income Tax Examination [Line Items]
Valuation allowance	9,653
Unused non-capital tax losses	$ 19,275

Taxes - Significant Components

Taxes - Significant Components of Future Income Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Tax loss carryforwards	$ 24,096	$ 26,155
Scientific research and experimental development ("SR&ED") carryforwards	5,051	5,051
Investment tax credits	4,151	4,151
Accounts payable and accrued liabilities	489	1,291
Difference between tax and book value of patent finance obligations	(153)	(343)
Difference between tax and book value of capital and intangible assets	306	(1,072)
Difference between tax and book value of loan receivable	14	27
Total future income tax asset	33,954	35,260
Valuation allowance	(19,308)	(17,583)
Net future income tax asset	$ 14,646	$ 17,677

Taxes - Summary of Tax Losses a

Taxes - Summary of Tax Losses and Scientific Research and Experimental Development Expenditure (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
SR&ED Expenditure Pool	$ 19,061
Tax Losses	71,999	$ 77,647
Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	52,724
U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	19,275
2030 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	1,146
2030 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	1,146
2031 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	3,043
2031 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	2,442
2031 [Member] | U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	601
2032 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	6,542
2032 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	4,458
2032 [Member] | U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	2,084
2033 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	31,510
2033 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	26,703
2033 [Member] | U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	4,807
2034 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	11,905
2034 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	4,276
2034 [Member] | U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	7,629
2035 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	6,043
2035 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	1,889
2035 [Member] | U.S. [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	4,154
2036 [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	11,810
2036 [Member] | Canada [Member]
Tax Credit Carryforward [Line Items]
Tax Losses	11,810
Indefinite [Member]
Tax Credit Carryforward [Line Items]
SR&ED Expenditure Pool	$ 19,061

Loan Receivable - Additional In

Loan Receivable - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 19, 2012	Dec. 31, 2016	Dec. 31, 2015
Accounts Notes And Loans Receivable [Line Items]
Term loan facility	$ 1,000
Estimated future cash flow projections, effective interest rate		18.00%
On first 10 million gross revenue [Member]
Accounts Notes And Loans Receivable [Line Items]
Gross revenue realized by borrower from patents acquired utilizing the term loan facility, company's entitlement percentage		15.00%
On all gross revenue over first 10 million [Member]
Accounts Notes And Loans Receivable [Line Items]
Gross revenue realized by borrower from patents acquired utilizing the term loan facility, company's entitlement percentage		10.00%
Term Loan [Member]
Accounts Notes And Loans Receivable [Line Items]
Percentage of interest on Term loan facility	15.00%	15.00%	15.00%
Term loan maturity date	Oct. 18, 2017

Loan Receivable - Carrying Valu

Loan Receivable - Carrying Value of Term Loan Facility (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Loans Receivable Net [Abstract]
15% Term loan facility	$ 1,000	$ 1,000
Unamortized discount	(36)	(70)
Accrued interest	802	567
Net carrying amount	$ 1,766	$ 1,497

Loan Receivable - Carrying Va43

Loan Receivable - Carrying Value of Term Loan Facility (Parenthetical) (Detail)	Dec. 31, 2016	Dec. 31, 2015	Oct. 19, 2012
Term Loan [Member]
Accounts Notes And Loans Receivable [Line Items]
Percentage of interest on Term loan facility	15.00%	15.00%	15.00%

Property and Equipment - Schedu

Property and Equipment - Schedule of Furniture and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Cost	$ 3,971	$ 4,337
Accumulated Depreciation	2,731	2,723
Net Book Value	1,240	1,614
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	1,373	1,373
Accumulated Depreciation	461	322
Net Book Value	912	1,051
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Cost	2,102	2,092
Accumulated Depreciation	1,882	1,843
Net Book Value	220	249
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	496	872
Accumulated Depreciation	388	558
Net Book Value	$ 108	$ 314

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Purchased property and equipment	$ 48	$ 178
Cost of disposed property and equipment	414
Accumulated amortization of disposed property and equipment	401
Loss on disposal of assets	$ 13	$ 15

Patents - Schedule of Patents (

Patents - Schedule of Patents (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Net Book Value	$ 123,351	$ 155,213
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	345,603	357,059
Accumulated Amortization	222,252	201,846
Net Book Value	$ 123,351	$ 155,213

Patents - Additional Informatio

Patents - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Purchase of patents	$ 1,660	$ 46,973
Amortization expense	$ 33,521	36,498
Non-cash, pre-tax charge on patents		$ 1,747
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, remaining useful lives	1 year
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, remaining useful lives	13 years

Patents - Estimated Future Amor

Patents - Estimated Future Amortization Expense of Patents (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Finite Lived Intangible Assets Net [Abstract]
2,017	$ 20,874
2,018	17,941
2,019	16,354
2,020	15,302
2,021	14,566
Estimated future amortization expense of patents	$ 85,037

Goodwill - Additional Informati

Goodwill - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment of goodwill	$ 0

Patent Finance Obligation - Add

Patent Finance Obligation - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 13, 2014	Jun. 18, 2014	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Current portion of obligation			$ 10,372	$ 8,085
Long term portion of obligation			$ 12,775	$ 19,895
Patent Rights Finance Obligation, Due June 18, 2023 [Member]
Debt Instrument [Line Items]
Discount rate		6.00%
Debt instrument, maturity date			Jun. 18, 2023	Jun. 18, 2023
Current portion of obligation			$ 5,129
Long term portion of obligation			$ 8,685
Patent Finance Obligation, Due August 18, 2018 [Member]
Debt Instrument [Line Items]
Discount rate	4.50%
Debt instrument, maturity date			Aug. 18, 2018	Aug. 18, 2018
Current portion of obligation			$ 5,243
Long term portion of obligation			$ 4,090
Discount payment stream	$ 1,389
Patent Finance Obligation, Due August 18, 2018 [Member] | Secured Term Debt [Member]
Debt Instrument [Line Items]
Secured term debt, term			5 years

Patent Finance Obligation - Cur

Patent Finance Obligation - Current and Long-Term Portions of Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Gross	$ 23,722	$ 29,277
Unamortized Discount	(575)	(1,297)
Net Carrying Amount	23,147	27,980
Current portion	(10,372)	(8,085)
Long term portion of obligation	12,775	19,895
Patent Rights Finance Obligation, Due June 18, 2023 [Member]
Debt Instrument [Line Items]
Gross	14,000	14,000
Unamortized Discount	(185)	(364)
Net Carrying Amount	13,815	13,636
Current portion	(5,129)
Long term portion of obligation	8,685
Patent Finance Obligation, Due August 18, 2018 [Member]
Debt Instrument [Line Items]
Gross	9,722	15,277
Unamortized Discount	(390)	(933)
Net Carrying Amount	9,332	$ 14,344
Current portion	(5,243)
Long term portion of obligation	$ 4,090

Patent Finance Obligation - C52

Patent Finance Obligation - Current and Long-Term Portions of Obligations (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Patent Rights Finance Obligation, Due June 18, 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Jun. 18, 2023	Jun. 18, 2023
Patent Finance Obligation, Due August 18, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Aug. 18, 2018	Aug. 18, 2018

Patent Finance Obligation - Sch

Patent Finance Obligation - Schedule of Payments Expected (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2,017	$ 10,556
2,018	11,166
2,019	2,000
Total	$ 23,722	$ 29,277

Accounts Payable and Accrued 54

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Trade payables	$ 913	$ 1,318
Accrued compensation	6,099	3,146
Accrued litigation costs	151	2,363
Dividends	1,102	1,091
Success fee obligation - current portion	585	2,983
Accrued contingent partner payments & legal fees	4,077	1,140
Patent acquisition liability	1,000	9,000
Accrued other	1,718	2,164
Accrued liabilities current	$ 15,645	$ 23,205

Accounts Payable and Accrued 55

Accounts Payable and Accrued Liabilities - Additional Information (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Payables And Accruals [Abstract]
Success fee obligation	$ 27,986

Accounts Payable and Accrued 56

Accounts Payable and Accrued Liabilities - Schedule of Current and Long Term Liability (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Success fee obligation	$ 632	$ 3,638
Current portion	(585)	(2,983)
Long term portion	$ 47	$ 655

Share Capital - Additional Info

Share Capital - Additional Information (Detail) CAD / shares in Units, CAD in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)shares	Dec. 31, 2016CADCAD / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2015CADshares	Dec. 31, 2016CADshares	Dec. 31, 2015CADshares
Schedule Of Capitalization Equity [Line Items]
Special preferred, redeemable, retractable, non-voting, Shares Authorized	6,350.9				6,350.9
Preference shares issued or outstanding	0				0
Purchase of common shares under NCIB	11,762,446		11,676,510		11,762,446	11,676,510
Stock Repurchase Program Expiration Date	Feb. 11, 2017	Feb. 11, 2017	May 28, 2016	May 28, 2016
Repurchased common shares under NCIB	2,398,500	2,398,500	125,000	125,000
Repurchased common shares under NCIB, Value | $	$ 4,225		$ 329
Increase in additional paid in capital | $	$ 4,276		114
Weighted average fair value per option granted | CAD / shares		CAD 0.98
Intrinsic value of options exercised | CAD					CAD 2	CAD 488
Fair value of options vested | CAD		CAD 956		CAD 1,634
Unrecognized stock-based compensation cost, net of expected forfeitures | CAD					CAD 154
Expected weighted average period for recognition of unrecognized compensation cost	2 years 2 months 1 day	2 years 2 months 1 day
Stock-based compensation | $	$ 217		$ 847
Anti-dilutive effect of options	5,985,454	5,985,454	8,071,056	8,071,056
Security Based Compensation Arrangements [Member]
Schedule Of Capitalization Equity [Line Items]
Common shares outstanding, Percent	10.00%	10.00%
DSU Plan [Member]
Schedule Of Capitalization Equity [Line Items]
Common shares authorized for issuance	430,000				430,000
Liability recorded in respect of outstanding stock-based compensation | $	$ 322		$ 367
Employee Stock Option [Member]
Schedule Of Capitalization Equity [Line Items]
Common shares authorized for issuance	800,000				800,000
Options vesting, Expiration date	6 years	6 years
Employee Stock Option [Member] | Minimum [Member]
Schedule Of Capitalization Equity [Line Items]
Options vesting period	3 years	3 years
Employee Stock Option [Member] | Maximum [Member]
Schedule Of Capitalization Equity [Line Items]
Options vesting period	4 years	4 years
Restricted Stock Units (RSUs) [Member]
Schedule Of Capitalization Equity [Line Items]
Options vesting period	3 years	3 years
Liability recorded in respect of outstanding stock-based compensation | $	$ 1,348		$ 684
Restricted stock units cancelled	125,491	125,491	783,112	783,112
2016 NCIB [Member]
Schedule Of Capitalization Equity [Line Items]
Repurchased common shares under NCIB, Value | $	$ 4,225
2015 NCIB [Member]
Schedule Of Capitalization Equity [Line Items]
Repurchased common shares under NCIB, Value | $			$ 329

Share Capital - Components of C

Share Capital - Components of Common Shares Issued and Outstanding (Detail) - shares	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Common shares	118,572,181	120,842,448	120,247,647
Total common shares outstanding including convertible equity instruments	124,755,002	129,173,902
DSU Plan [Member]
Class of Stock [Line Items]
Securities convertible into common shares	197,367	260,398
Stock options [Member]
Class of Stock [Line Items]
Securities convertible into common shares	5,985,454	8,071,056

Share Capital - Schedule of Com

Share Capital - Schedule of Common Stock (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Capitalization Equity [Line Items]
Beginning balance, Shares	120,842,448	120,247,647
Issued on exercise of stock options, Shares	4,333	625,201
Issued on sale of shares under Employee Share Purchase Plan, Shares	70,600	94,600
Conversion of deferred stock units to common shares	53,300
Repurchased under normal course issuer bid, Shares	(2,398,500)	(125,000)
Ending balance, Shares	118,572,181	120,842,448
Beginning balance	$ 427,781	$ 426,037
Issued on exercise of stock options	11	1,269
Transfer from additional paid-in capital on exercise of options	6	787
Issued on sale of shares under Employee Share Purchase Plan	72	131
Conversion of deferred stock units to common shares	116
Repurchased under normal course issuer bid	(4,225)	(329)
Ending balance	$ 419,485	$ 427,781
Capital Stock [Member]
Schedule Of Capitalization Equity [Line Items]
Repurchased under normal course issuer bid, Shares	(2,398,500)	(125,000)
Issued on exercise of stock options	$ 17	$ 2,056
Issued on sale of shares under Employee Share Purchase Plan	72	131
Conversion of deferred stock units to common shares	116
Repurchased under normal course issuer bid	$ (8,501)	$ (443)

Share Capital - Schedule of Qua

Share Capital - Schedule of Quarterly Cash Dividends Paid (Detail) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2016USD ($)

Dec. 31, 2016CAD / shares

Sep. 30, 2016USD ($)

Sep. 30, 2016CAD / shares

Jun. 30, 2016USD ($)

Jun. 30, 2016CAD / shares

Mar. 31, 2016USD ($)

Mar. 31, 2016CAD / shares

Dec. 31, 2015USD ($)

Dec. 31, 2015CAD / shares

Sep. 30, 2015USD ($)

Sep. 30, 2015CAD / shares

Jun. 30, 2015USD ($)

Jun. 30, 2015CAD / shares

Mar. 31, 2015USD ($)

Mar. 31, 2015CAD / shares

Dec. 31, 2016USD ($)

Dec. 31, 2016CAD / shares

Dec. 31, 2015USD ($)

Dec. 31, 2015CAD / shares

Equity [Abstract]

Cash dividends, Per Share | CAD / shares

CAD 0.0125

CAD 0.0125

CAD 0.0125

CAD 0.0125

CAD 0.0525

CAD 0.0525

CAD 0.0525

CAD 0.0500

CAD 0.0500

CAD 0.2075

Cash dividends paid | $

$ 1,132

$ 1,153

$ 1,151

$ 1,091

$ 4,817

$ 5,077

$ 5,005

$ 5,183

$ 4,527

$ 20,082

Share Capital - Schedule of Dec

Share Capital - Schedule of Declared Quarterly Dividends (Detail) - CAD / shares	3 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Equity [Abstract]
Dividends declared	CAD 0.0125	CAD 0.0125	CAD 0.0125	CAD 0.0125	CAD 0.0125	CAD 0.0525	CAD 0.0525	CAD 0.0525

Share Capital - Schedule of Opt

Share Capital - Schedule of Option Activity (Detail) - CAD / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Number of Options	8,071,056	9,465,372
Granted, Number of Options	256,477
Exercised, Number of Options	(4,333)	(625,201)
Forfeited, Number of Options	(86,999)	(769,115)
Expired, Number of Options	(2,250,747)
Ending balance, Number of Options	5,985,454	8,071,056
Exercise Price Range, lower range	CAD 2.84	CAD 1.42	CAD 1.42
Exercise Price Range, upper range	5.66	7.09	CAD 7.09
Beginning balance, Weighted Average, Price per Share	4.86	4.63
Granted, Weighted Average, Price per Share	2.86
Exercised, Weighted Average, Price per Share	3.28	2.53
Forfeited, Weighted Average, Price per Share	3.84	3.97
Expired, Weighted Average, Price per Share	4.85
Ending balance, Weighted Average, Price per Share	CAD 4.78	CAD 4.86
Number of Exercisable Options	5,617,312	7,062,972	6,760,992
Weighted Average Price of Exercisable Options	CAD 4.89	CAD 4.97	CAD 4.83
Granted [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range, lower range	2.84
Exercise Price Range, upper range	3.32
Exercised [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range, lower range	3.12	2.53
Exercise Price Range, upper range	3.33	2.53
Forfeited [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range, lower range	3.49	2.53
Exercise Price Range, upper range	4.37	CAD 5.52
Expired [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range, lower range	3.40
Exercise Price Range, upper range	CAD 7.09

Share Capital - Estimated Fair

Share Capital - Estimated Fair Value of Options Granted, Weighted Average Assumptions (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Risk free interest rate	0.90%
Volatility	49.00%
Expected option life (in years)	5 years 7 months 6 days	4 years 8 months 12 days
Dividend yield	3.20%
Forfeiture rate	14.50%

Share Capital - Details of Outs

Share Capital - Details of Outstanding Options (Detail) - CAD / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding Options at December 31, 2016	5,985,454	8,071,056	9,465,372
Weighted Average Price of Outstanding Options	CAD 4.78	CAD 4.86	CAD 4.63
Exercisable Options at December 31, 2016	5,617,312	7,062,972	6,760,992
Exercise Price, Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Range of Exercise Price	CAD 2.84
Upper Range of Exercise Price	CAD 3
Outstanding Options at December 31, 2016	246,477
Remaining Term of Options in Years	5 years 6 months 29 days
Weighted Average Price of Outstanding Options	CAD 2.84
Exercise Price, Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Range of Exercise Price	3.01
Upper Range of Exercise Price	CAD 4
Outstanding Options at December 31, 2016	757,167
Remaining Term of Options in Years	2 years 11 months 5 days
Weighted Average Price of Outstanding Options	CAD 3.43
Exercisable Options at December 31, 2016	660,502
Weighted Average Price of Exercisable Options	CAD 3.44
Exercise Price, Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Range of Exercise Price	4.01
Upper Range of Exercise Price	CAD 5
Outstanding Options at December 31, 2016	1,500,800
Remaining Term of Options in Years	2 years 2 months 9 days
Weighted Average Price of Outstanding Options	CAD 4.45
Exercisable Options at December 31, 2016	1,475,800
Weighted Average Price of Exercisable Options	CAD 4.46
Exercise Price, Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Range of Exercise Price	5.01
Upper Range of Exercise Price	CAD 6
Outstanding Options at December 31, 2016	3,481,010
Remaining Term of Options in Years	7 months 6 days
Weighted Average Price of Outstanding Options	CAD 5.36
Exercisable Options at December 31, 2016	3,481,010
Weighted Average Price of Exercisable Options	CAD 5.36
Exercise Price, Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Range of Exercise Price	2.84
Upper Range of Exercise Price	CAD 6
Outstanding Options at December 31, 2016	5,985,454
Remaining Term of Options in Years	1 year 6 months
Weighted Average Price of Outstanding Options	CAD 4.78
Exercisable Options at December 31, 2016	5,617,312
Weighted Average Price of Exercisable Options	CAD 4.89

Share Capital - Summary of Stoc

Share Capital - Summary of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 217	$ 847
Cost of revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	174	460
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation		81
Marketing, general and administration [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 43	$ 306

Share Capital - Summary of Defe

Share Capital - Summary of Deferred Stock Units (Detail) - DSU Plan [Member] - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	260,398	244,526
Issued in lieu of quarterly fees	21,936	5,000
Issued in lieu of dividends paid	14,690	10,872
Settled for cash	(46,357)
Settled for common shares	(53,300)
Ending Balance	197,367	260,398

Share Capital - Summary of Rest

Share Capital - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	1,509,032	1,294,278
Granted	2,477,861	1,101,021
Settled	(1,148,892)	(103,155)
Forfeited	(125,491)	(783,112)
Ending Balance	2,712,510	1,509,032

Share Capital - Weighted Averag

Share Capital - Weighted Average Number of Common Shares Outstanding Used in Basic and Diluted Earnings per Share Computation (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Basic weighted average common shares outstanding	119,245,581	120,713,535
Effect of options		6,636
Diluted weighted average common shares outstanding	119,245,581	120,720,171

Financial Instruments - Summary

Financial Instruments - Summary of Estimated Fair Values of Entity's Financial Instruments (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents, Carrying Amount	$ 106,553	$ 93,431	$ 126,311
Short-term investments, Carrying Amount	1,154	1,120
Loan receivable, Carrying Amount	1,766	1,497
Patent finance obligations, Carrying Amount	23,147	27,980
Hierarchy Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents, Carrying Amount	106,553	93,431
Short-term investments, Carrying Amount	1,154	1,120
Cash and cash equivalents, Fair Value	106,553	93,431
Short-term investments, Fair Value	1,154	1,120
Hierarchy Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Loan receivable, Carrying Amount	1,766	1,497
Patent finance obligations, Carrying Amount	23,146	27,980
Loan receivable, Fair Value	1,766	1,497
Patent finance obligations, Fair Value	$ 23,146	$ 27,980

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) CAD in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)Customer	Dec. 31, 2016CADCustomer	Dec. 31, 2015USD ($)Customer	Dec. 31, 2015CADCustomer	Jan. 31, 2017USD ($)	Dec. 31, 2016CAD	Dec. 31, 2015CAD
Financing Receivable Recorded Investment Past Due [Line Items]
Provision for doubtful debts | $	$ 138,000		$ 11,000
Cash and cash equivalent and short-term investments | $	107,707,000
Amount of credit facilities, available						CAD 8,000
Accounts receivable (Note 11) | $	20,357,000		8,436,000
Amount of credit facilities, available for general corporate purposes						8,000
Amount of credit facilities, available for foreign exchange facility						2,000
Borrowings under credit facility | $	0
One percent increase/decrease in interest rates resulting to interest income | $	1,077,000
Revenues denominated value		CAD 0		CAD 0
Expenses denominated value		14,019		17,912
Fluctuations in foreign currency rates		14,019		17,912
One cent increase/decrease in foreign currency resulting comprehensive loss | $	1,144,000		$ 30,000
Foreign Exchange Forward Contracts [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Foreign exchange forward contracts loss | $	$ 0
Cash and Cash Equivalents [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Asset, Reporting currency denominated value						5,235	CAD 5,394
Cash And Cash Equivalents And Short-Term Investments And Accounts Receivable [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Fluctuations in foreign currency rates		CAD 3,873		CAD 349
Accounts Payable And Accrued Liabilities
Financing Receivable Recorded Investment Past Due [Line Items]
Liabilities, Reporting currency denominated value						9,108	5,047
Canada [Member] | Prime Rate [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Basis spread on variable rate	1.00%	1.00%
U.S. [Member] | Base Rate [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Basis spread on variable rate	1.00%	1.00%
Subsequent Event [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Past due amount collected | $					$ 0
Accounts Receivable [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Asset, Reporting currency denominated value						CAD 0	CAD 3
Revenue from Rights Concentration Risk [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Number of major licensees | Customer	3	3	3	3
Revenue from Rights Concentration Risk [Member] | Revenue, Rights Granted [Member] | Licensee One [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	18.00%	18.00%	16.00%	16.00%
Revenue from Rights Concentration Risk [Member] | Revenue, Rights Granted [Member] | Licensee Two [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	14.00%	14.00%	12.00%	12.00%
Revenue from Rights Concentration Risk [Member] | Revenue, Rights Granted [Member] | Licensee Three [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	11.00%	11.00%	10.00%	10.00%
Credit Concentration Risk [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Number of major licensees | Customer	2	2	3	3
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Licensee One [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	80.00%	80.00%	47.00%	47.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Licensee Two [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	16.00%	16.00%	15.00%	15.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Licensee Three [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage			10.00%	10.00%
Currency Denomination Concentration Risk [Member] | Cash And Cash Equivalents and Short Term Investments [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Concentration risk percentage	5.00%	5.00%

Financial Instruments - Informa

Financial Instruments - Information Regarding Aging and Collectability of Accounts Receivable (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Financing Receivable Recorded Investment Past Due [Line Items]
Total accounts receivable	$ 20,357	$ 8,436
Trade Accounts Receivable [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Current	20,311
Less allowance for doubtful accounts	138
Total accounts receivable	20,357
Trade Accounts Receivable [Member] | Past due 1 - 30 days [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, past due	19
Trade Accounts Receivable [Member] | Past due 31 - 60 days [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, past due	7
Trade Accounts Receivable [Member] | Over 91 days past due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, past due	$ 158

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Aggregate Minimum Annual Lease Payments under Operating Lease (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 652
2,018	568
2,019	497
2,020	358
2021 and thereafter	1,075
Total annual lease payments	$ 3,150

Commitments and Contingencies73

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Accrued partner program royalties	$ 832	$ 669
Accrued partner program royalties outstanding	$ 121	$ 538

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Percentage of workforce reduction	30.00%
Restructuring charge		$ 1,302
Workforce Reduction [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 1,272	1,272
Lease Obligation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 30	$ 30

Restructuring Charges - Summary

Restructuring Charges - Summary of Restructuring Charges and Related Reserves (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring charge			$ 1,302
Cash payments		$ (533)	(769)
Balance of provision			533
Workforce Reduction [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 1,272		1,272
Cash payments		(512)	(760)
Balance of provision			512
Lease Obligation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 30		30
Cash payments		$ (21)	(9)
Balance of provision			$ 21

Supplemental Cash Flow Inform76

Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement Of Cash Flows [Abstract]
Net interest received in cash, included in operations	$ (206)	$ (207)
Taxes paid	5,699	3,623
Patent acquisition liability	$ 1,000	$ 9,000

Related-Party Transaction - Add

Related-Party Transaction - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Director
Related Party Transaction [Line Items]
Consulting services fees paid	$ 8	$ 100